GlassScriptPhysician profile
Damian A Laber
NPI 1922089747
$753,212.61
in general payments reported to CMS, 2019-2025
16 companies · $3,726 in 2025
The $3,726 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443K · 2020: $46K · 2021: $84K · 2022: $134K · 2023: $25K · 2024: $17K · 2025: $3,726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $36K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,610 · Travel and Lodging: $1,970 · Food and Beverage: $1,232 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $35,992.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,610.00 |
| Travel and Lodging | $1,969.57 |
| Food and Beverage | $1,232.19 |
| Education | $173.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $271,213.68 | 2019-2025 | Ultomiris, Soliris |
| E.R. Squibb & Sons, L.L.C. | $145,087.03 | 2019 | |
| Genzyme Corporation | $87,956.37 | 2019-2023 | |
| Ipsen Biopharmaceuticals, INC | $69,895.49 | 2020-2023 | Onivyde |
| Genentech USA, INC. | $51,705.44 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $44,564.44 | 2019 | |
| Apellis Pharmaceuticals, INC. | $35,187.90 | 2021-2022 | |
| Lilly USA, LLC | $28,048.31 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $6,315.38 | 2024-2025 | |
| Csl Behring | $6,122.66 | 2019 | |
| Seagen INC. | $3,443.68 | 2019 | |
| Astellas Pharma US INC | $1,751.22 | 2020-2023 | |
| Karyopharm Therapeutics INC. | $1,550.00 | 2021 | |
| Foundation Medicine, INC. | $126.56 | 2020 | |
| Glaxosmithkline, LLC. | $123.33 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $121.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Damian Laber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.